Drug
Immune Globulin
Immune Globulin: highest development phase Post-Market, developed by CSL, Grifols. 5 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- CSL, Grifols
Trials
| Drug | Phase | Indication |
|---|---|---|
| Subcutaneous Immune Globulin (Human) (Hizentra) NCT02711228 | Post-Market | Primary Immune Deficiency |
| Immune globulin subcutaneous (Human) NCT01458171 | Phase 3 | Primary Immune Deficiency Disorder |
| Immune globulin subcutaneous (Human) NCT01461018 | Phase 3 | Primary Immune Deficiency |
| Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified NCT00220740 | Phase 3 | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating |
| Intravenous Immune Globulin NCT04432324 | Phase 2 | COVID-19 |
Latest
No recent events.
Follow Immune Globulin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.